Crinetics Pharmaceuticals, Inc.
DE ˙ DB ˙ US22663K1079
27,79 € ↑0,30 (1,09%)
2026-06-04
DELAT PRIS
SecurityDE:6Z4 / Crinetics Pharmaceuticals, Inc.
InstitutionAlliancebernstein L.p.
Latest Disclosed Ownership170,949 shares
Latest Disclosed Value $ 7,957,676
Alliancebernstein L.p. reports 83.78% increase in ownership of 6Z4 / Crinetics Pharmaceuticals, Inc.

On May 15, 2026 - Alliancebernstein L.p. filed a 13F-HR form disclosing ownership of 170,949 shares of Crinetics Pharmaceuticals, Inc. (DE:6Z4) valued at $5,060,090 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 93,020 shares of Crinetics Pharmaceuticals, Inc.. This represents a change in shares of 83.78% during the quarter. The current value of the position is $4,750,673 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 170,949 77,929 83.78 7,958 83.76 0.0026
2026-02-17 2025-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 93,020 0 0.00 4,330 11.77 0.0014
2025-11-14 2025-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 93,020 0 0.00 3,874 44.82 0.0012
2025-08-14 2025-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 93,020 -17,654 -15.95 2,675 -27.94 0.0009
2025-05-15 2025-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 110,674 8,954 8.80 3,712 -28.62 0.0013
2025-02-12 2024-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 101,720 9,190 9.93 5,201 9.98 0.0018
2024-11-14 2024-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 92,530 0 0.00 4,728 14.09 0.0016
2024-08-14 2024-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 92,530 25,260 37.55 4,144 31.64 0.0014
2024-05-14 2024-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 67,270 0 0.00 3,149 31.55 0.0011
2024-02-14 2023-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 67,270 6,130 10.03 2,393 31.63 0.0009
2023-11-14 2023-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 61,140 9,940 19.41 1,818 97.18 0.0008
2023-08-15 2023-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 51,200 0 0.00 923 12.17 0.0004
2023-05-15 2023-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 51,200 0 0.00 822 -12.18 0.0004
2023-02-15 2022-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 51,200 0 0.00 937 -6.96 0.0004
2022-11-15 2022-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 51,200 0 0.00 1,006 5.34 0.0005
2022-08-15 2022-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 51,200 21,600 72.97 955 46.92 0.0004
2022-05-13 2022-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 29,600 100 0.34 650 -22.43 0.0003
2022-02-14 2021-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 29,500 0 0.00 838 34.94 0.0003
2021-11-10 2021-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 29,500 0 0.00 621 11.69 0.0002
2021-07-30 2021-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 29,500 2,700 10.07 556 35.61 0.0002
2021-05-06 2021-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 26,800 -1,100 -3.94 410 4.06 0.0002
2021-02-08 2020-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 27,900 2,000 7.72 394 -2.96 0.0002
2020-11-12 2020-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 25,900 0 0.00 406 -10.57 0.0002
2020-08-13 2020-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 25,900 11,100 75.00 454 108.26 0.0003
2020-05-14 2020-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 14,800 3,000 25.42 218 -26.35 0.0002
2020-02-18 2019-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 11,800 600 5.36 296 76.19 0.0002
2019-11-14 2019-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 11,200 2,200 24.44 168 -25.33 0.0001
2019-08-14 2019-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 9,000 9,000 225 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.